United Therapeutics Co. (NASDAQ:UTHR) Stock Position Raised by CIBC Asset Management Inc

CIBC Asset Management Inc lifted its position in United Therapeutics Co. (NASDAQ:UTHR) by 4.2% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,598 shares of the biotechnology company’s stock after acquiring an additional 65 shares during the quarter. CIBC Asset Management Inc’s holdings in United Therapeutics were worth $564,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics in the 4th quarter valued at approximately $25,000. Brooklyn Investment Group purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $33,000. Capital Performance Advisors LLP purchased a new stake in shares of United Therapeutics in the 3rd quarter valued at approximately $82,000. MassMutual Private Wealth & Trust FSB lifted its position in shares of United Therapeutics by 31.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares in the last quarter. Finally, Values First Advisors Inc. acquired a new position in United Therapeutics in the 3rd quarter valued at approximately $90,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.

United Therapeutics Trading Down 1.7 %

NASDAQ UTHR opened at $361.10 on Friday. The company has a fifty day simple moving average of $362.68 and a 200 day simple moving average of $360.45. The company has a market cap of $16.12 billion, a P/E ratio of 15.86, a P/E/G ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a 1 year low of $214.75 and a 1 year high of $417.82.

Insider Buying and Selling

In related news, Director Louis W. Sullivan sold 26,209 shares of the company’s stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the completion of the sale, the director now directly owns 5,051 shares of the company’s stock, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $372.75, for a total transaction of $3,727,500.00. Following the sale, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $960,576.75. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 124,164 shares of company stock valued at $45,398,793. Company insiders own 11.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on UTHR. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Oppenheimer upped their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. The Goldman Sachs Group upped their price objective on shares of United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a research note on Friday, November 1st. Argus upped their price objective on shares of United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.